Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015 (2015), Article ID 516740, 12 pages
http://dx.doi.org/10.1155/2015/516740
Review Article

The Utility of Iron Chelators in the Management of Inflammatory Disorders

1Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, 5850 College St., Halifax, NS, Canada B3H 1X5
2Department of Microbiology and Immunology, Dalhousie University, 5850 College Street, Halifax, NS, Canada B3H 1X5
3Department of Pharmacology, Dalhousie University, 5850 College St., Halifax, NS, Canada B3H 1X5
4Department of Pharmacy, East West University, Plot No. A/2, Jahurul Islam City, Aftabnagar, Dhaka 1219, Bangladesh
5Department of Pathology, Dalhousie University, 5850 College St., Halifax, NS, Canada B3H 1X5
6Department of Physiology, Faculty of Medicine, Cairo University, 1 Al-Saray St., Cairo 11559, Egypt
7Chelation Partners Inc., 1411 Oxford St., Halifax, NS, Canada B3H 3Z1

Received 20 June 2014; Revised 1 September 2014; Accepted 1 September 2014

Academic Editor: Yung-Hsiang Chen

Copyright © 2015 C. Lehmann et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Since iron can contribute to detrimental radical generating processes through the Fenton and Haber-Weiss reactions, it seems to be a reasonable approach to modulate iron-related pathways in inflammation. In the human organism a counterregulatory reduction in iron availability is observed during inflammatory diseases. Under pathological conditions with reduced or increased baseline iron levels different consequences regarding protection or susceptibility to inflammation have to be considered. Given the role of iron in development of inflammatory diseases, pharmaceutical agents targeting this pathway promise to improve the clinical outcome. The objective of this review is to highlight the mechanisms of iron regulation and iron chelation, and to demonstrate the potential impact of this strategy in the management of several acute and chronic inflammatory diseases, including cancer.